Navigation Links
Safeway Inc. and the Prostate Cancer Foundation to Fund Landmark Prostate Cancer Research Collaboration
Date:11/15/2007

S.T.A.R Program Brings Together Researchers from North America's Leading Prostate Cancer Centers

WASHINGTON, Nov. 15 /PRNewswire/ -- Safeway Inc. and the Prostate Cancer Foundation today announced they will collectively donate $6 million to fund the S.T.A.R. Program (for Special Team Amplification of Research), an innovative research initiative focused on exploring the role of targeted heat in cancer therapy to treat prostate cancer, as well as other research strategies.

The S.T.A.R. Program is being launched for the first phase of research and development with a $3 million grant from the Safeway Foundation which raised the funds from its customers with donations made at checkout. The Prostate Cancer Foundation (PCF) developed the collaborative research partnership and matched the initial funds dollar-for-dollar, for a total $6 million commitment. PCF is the world's largest philanthropic source of support for prostate cancer research and has funded ten of the individual scientists making up the S.T.A.R. North American team.

The program brings together an interdisciplinary team of investigators from multiple prominent cancer research centers. The team consists of investigators from the Johns Hopkins University School of Medicine (program lead and coordinator), the University of Michigan Cancer Center and the University of British Columbia.

Additional expertise will be leveraged through the Prostate Cancer Foundation from the University of Washington, and from M.D. Anderson Cancer Center and Emory University. This unique program will bring expertise throughout the cancer research and treatment communities to focus on a new approach to prostate cancer treatment. "Similar to the program that Robert Goddard put in place to make space flight a reality, everyone that has input will be invited to the table to be part of the solution," noted Jonathan Simons, M.D., CEO and President of the Prostate Cancer Foundation.

"The S.T.A.R. Pro
'/>"/>

SOURCE Safeway Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...TRIANGLE PARK, N.C., Dec. 1 Max Ne...have expanded over the years serving the top most ...ich was originally set up in an area of 2000 sq. f...part of the suite of services by Max Neeman, are r...ble offering. ,, The pharmacy inventory managem...
(Date:12/1/2009)... Dec. 1 Individuals in ...ly than those with traditional coverage to exhibit...engaged in wellness programs, and to be more incli...olding down costs, according to survey results rel...search Institute (EBRI). ,, At the same time, ...
(Date:12/1/2009)...RDALE, Fla., Dec. 1 OrbusNeich tod...in the randomized clinical trial of the Combo Bio-...,, A prospective, randomized, multicenter study...u M inal sirolimus coat ED bio- E ngineered...ites in Asia, Australia, Europe and South America ...
(Date:12/1/2009)...California are unable to successfully obtain infor... despite recent state legislation intended to impr..., Posing as low-income uninsured patients, resea...-third of the hospitals they approached and the es... allowed under California law, according to the fi...
(Date:12/1/2009)... Lumension announces general availability of its ...ver end-to-end endpoint management capabilities on...nt console architecture. , ...sion, a global leader in endpoint management and s...dpoint Management and Security Suite (LEMSS) tha...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6
...lease is available in French . , A collaborati...ogical Institute (MNI), McGill University has demo... and cortical thickness in the brains of healthy 6... week in a special issue of scientific journal In...
...Texas, March 25 ULURU Inc. (NYSE Alternext: ULU) ...ce call to discuss the fourth quarter and year end...siness update on Tuesday, March 31, 2009 at 10:00 ...304#) five to ten minutes prior to the initiation ...
...e Call Today to Follow Release , , DENVER, March ... or the "Company") (OTC Bulletin Board: GLOB), an ...logy company, will report its fourth quarter and y...p://www.newscom.com/cgi-bin/prnh/20040226/GLOBALME...
...tive growths 3 times more likely regardless of age...h 25 (HealthDay News) -- Black women are three tim...p aggressive breast cancer, a U.S. study finds. , ...k women do get breast cancer, it,s often more adva...
...y 20 March, US researcher Dr. Chris Beecher from t...ture about sarcosine, an N-methyl derivative of th...ess in Stockholm, Sweden. Dr Beecher is a colleagu... with prostate cancer. These findings suggest that...
... March 25 An amazing medical discovery that provi... (ED) is in the US and looking to make the big th... News Release, go to: http://www.prnewswire.com/m...te Hydropump reverses Erectile Dysfunction throu...
Other Medicine News:Health News:When it comes to intelligence, size matters 2Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update 2Health News:Global Med Technologies(R), Inc. to Report Fourth Quarter and Year End Financial Results Today 2Health News:Black Women at Higher Risk for Aggressive Breast Tumors 2Health News:A new approach to prostate cancer detection 2Health News:Video: Bathmate Hydropump Poised to Replace Cialis, Levitra, and Viagra 2
(Date:12/1/2009)..., , ALBUQUERQUE, N.M., Dec. 1 /PRNewswire/ -...s laboratory that discovers, develops and markets ...ointment of Scott Glenn as chairman of the company... ,, Prior to joining Exagen, Glenn was managing... of a number of successful biomedical companies in...
(Date:12/1/2009)..., , CHENGDU, China, Dec. 1 /PRNews..., Inc., (NYSE Amex: TPI ), a manufacturer and sup..."TCM") based in Chengdu, China, today,announced th...e Food and Drug,Administration (SFDA) to produce P...m of 10 ml/tube (SFDA approval number Z20093060) a...
(Date:12/1/2009)..., , BEIJING, Dec. 1 /PRNewswire-A...ding provider of biopharmaceutical products in Chi...h purchase order for its H1N1 vaccine, PANFLU.1(TM...on Technology for the national,purchase plan. Unde...uce an,additional one million doses of PANFLU.1 (T...
Breaking Medicine Technology:Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 3Selective Insurance Group Announces Officer Appointments 56161 1Selective Insurance Group Announces Officer Appointments 56161 2Selective Insurance Group Announces Officer Appointments 56161 3XLHealth Appoints New Controller to Lead Financial Compliance Accounting Initiatives 56160 1XLHealth Appoints New Controller to Lead Financial Compliance Accounting Initiatives 56160 2Kroger Selects WaveSense Diabetes Testing Products 56156 1Kroger Selects WaveSense Diabetes Testing Products 56156 2
...N DIEGO, July 28 Cadence Pharmaceuticals,Inc. (Na... on in-licensing,developing and commercializing pr...n the hospital setting, today announced that it wi...fore the market opens on Thursday,August 7, 2008.,...nd live webcast to,discuss the financial results a...
...Two Large-Scale Analyses Have Conflicting Results ...in memory and thinking processes among placebo gro...educe the ability to show the effectiveness,of new...ported today at the,2008 Alzheimer,s Association I...AD 2008) in Chicago., Alzheimer clinical trials s...
Other Medicine Technology:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 3Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 4Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 5
...channel within a 12.1mm insertion tube. It featur...d image for improved reliability, an electronic be...5 and 5.0mhz transducer for deeper ultrasound imag...ical orientation and vascular evaluation during re...
...of diagnosis by using the Convex Scanning method. ...od flow by using the Color Flow Mapping and Color ...rated and the balloon fixation has improved. Those...curate techniques. The FG-36UX expands the possibi...
ACL 1000 Coagulation Analyzer
SYNCHRON CX®5 Delta
Medicine Products: